← Leaderboards
Joshi James Alumkal
Fred Hutchinson Cancer Research Center
$6,560,072
Attributed
$6,560,072
Total exposure
8
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.1M · FY2013–25$2M$1.5M$1M$500K$0
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,560,072 · 8
By mechanism
R01$5,037,537 · 4
P50$1,522,535 · 4
Top collaborators
No co-investigators on record.
Most similar at Fred Hutchinson Cancer Research Center
Same institution · by research overlap
- Colm M Morrissey$3,479,548
- Matthew L Fero$2,255,800
- Gavin Ha$4,673,787
- Mads Daugaard$838,161
Others in their field
Top investigators on “Malignant Neoplasm Of Prostate”
- David Heimbrook · Leidos Biomedical Research, Inc.$255,843,614
- Leonard Freedman · Leidos Biomedical Research, Inc.$63,277,106
- Walter John Curran · Thomas Jefferson University$61,298,085
- Norman Wolmark · Nsabp Foundation, Inc.$54,888,134
- James J. Dignam · University Of Chicago$48,310,409
- Laurence H Baker · University Of Michigan At Ann Arbor$43,366,962
Research focus
Malignant Neoplasm Of ProstateTumorProteinsChromatinCell SurvivalIn VitroTranscriptome SequencingGene ExpressionImplantClinical TrialsProstate Cancer CellGenesAndrogen ReceptorResistance MechanismPathway InteractionsIn VivoTumor GrowthChip-SeqCastrationDesignPhase I Clinical TrialsLoss Of FunctionGrowthGenetic Transcription
Grant awards (20)
Developing New Treatment Strategies for Neuroendocrine Prostate Cancer$531,228
R01 · FY2025 · CA · contact PI
Targeting Early Drivers of Prostate Cancer Lineage Plasticity$509,246
R01 · FY2025 · CA · contact PI
Career Enhancement Program$61,277
P50 · FY2025 · CA · contact PI
Developing New Treatment Strategies for Neuroendocrine Prostate Cancer$496,079
R01 · FY2024 · CA · contact PI
Targeting Prostate Cancer Lineage Plasticity with BET Bromodomain Inhibition$377,601
R01 · FY2024 · CA · contact PI
Targeting Prostate Cancer Lineage Plasticity with BET Bromodomain Inhibition$390,963
R01 · FY2023 · CA · contact PI
Targeting Prostate Cancer Lineage Plasticity with BET Bromodomain Inhibition$376,931
R01 · FY2022 · CA · contact PI
Targeting LSD1 in Neuroendocrine Prostate Cancer$230,315
P50 · FY2022 · CA · contact PI
Targeting Prostate Cancer Lineage Plasticity with BET Bromodomain Inhibition$372,389
R01 · FY2021 · CA · contact PI
Targeting LSD1 in Neuroendocrine Prostate Cancer$274,149
P50 · FY2021 · CA · contact PI
Targeting Prostate Cancer Lineage Plasticity with BET Bromodomain Inhibition$394,446
R01 · FY2020 · CA · contact PI
Targeting LSD1 in Neuroendocrine Prostate Cancer$351,000
P50 · FY2020 · CA · contact PI
The Role of LSD1 in the Evolution of Castration Resistant Prostate Cancer$317,240
R01 · FY2018 · CA · contact PI
The Role of LSD1 in the Evolution of Castration Resistant Prostate Cancer$316,934
R01 · FY2017 · CA · contact PI
The Role of LSD1 in the Evolution of Castration Resistant Prostate Cancer$316,934
R01 · FY2016 · CA · contact PI
The Role of LSD1 in the Evolution of Castration Resistant Prostate Cancer$316,575
R01 · FY2015 · CA · contact PI
Targeting LSD1 in Prostate Cancer$237,805
P50 · FY2015 · CA · contact PI
The Role of LSD1 in the Evolution of Castration Resistant Prostate Cancer$320,971
R01 · FY2014 · CA · contact PI
Targeting LSD1 in Prostate Cancer$218,980
P50 · FY2014 · CA · contact PI
Targeting LSD1 in Prostate Cancer$149,009
P50 · FY2013 · CA · contact PI